Golden
PACT Pharma

PACT Pharma

PACT Pharma is synthesizing neo-epitope targeted T cells and producing a personalized adoptive cell therapy designed to benefit each cancer patient.

All edits

Edits on 17 Nov 2018
Jude Gomila
Jude Gomila approved a suggestion from Golden's AI on 17 Nov 2018 12:24 am
Edits made to:
Article (+0/-0 images) (+0/-0 videos) (+13/-13 characters)

Article

PACT Pharma raised $95 million in Series B financing. Alphabet Inc.Alphabet Inc.'s venture arm GV led the round, with participation from Invus Group, Canaan Partners, Casdin Capital, Wu Capital and other undisclosed investors.

Edits on 2 Oct 2018
Carla Faraguna
Carla Faraguna edited on 2 Oct 2018 12:43 am
Edits made to:
Thumbnail
Description (+0/-37 characters)
Article (+0/-0 images) (+0/-0 videos) (+2/-8 characters)
Categories (+1/-0 topics)
Topic thumbnail

PACT Pharma

PACT Pharma is dedicated to synthesizing a tsunami of neo-epitope targeted T cells and producing a personalized adoptive cell therapy designed to benefit each individual cancer patient.

Article

The technology in development at PACT Pharma aims to reprogram immune systems to target and eradicate the cancer. PACT Pharma is engineering synthetic tumor-infiltrating lymphocytes (synthetic TILs), tailored for each patient's cancer with highly efficient turnaround in manufacturing from tumor biopsy to re-infusion of autologous synthetic TILs back into the patient.

Categories

Edits on 21 Sep 2018
Carla Faraguna
Carla Faraguna edited on 21 Sep 2018 9:18 pm
Edits made to:
Thumbnail
Description (+186/-0 characters)
Article (+0/-0 images) (+0/-0 videos) (+582/-0 characters)
Related Topics (+2/-0 topics)
Topic thumbnail

PACT Pharma

PACT Pharma is dedicated to synthesizing a tsunami of neo-epitope targeted T cells and producing a personalized adoptive cell therapy designed to benefit each individual cancer patient.

Article

The technology in development at PACT Pharma aims to reprogram immune systems to target and eradicate the cancer. PACT Pharma is engineering synthetic tumor-infiltrating lymphocytes (synthetic TILs), tailored for each patient's cancer with highly efficient turnaround in manufacturing from tumor biopsy to re-infusion of autologous synthetic TILs back into the patient.

...

PACT Pharma raised $95 million in Series B financing. Alphabet Inc.'s venture arm GV led the round, with participation from Invus Group, Canaan Partners, Casdin Capital, Wu Capital and other undisclosed investors.

Related Topics

Edits on 21 Sep 2018
Carla Faraguna"Initial topic creation"
Carla Faraguna created this topic on 21 Sep 2018 12:07 am
Edits made to:
Name
Thumbnail
Article
Topic thumbnail

 PACT Pharma

PACT Pharma is synthesizing neo-epitope targeted T cells and producing a personalized adoptive cell therapy designed to benefit each cancer patient.

No more activity to show.